{"id":10377,"date":"2026-06-30T10:41:44","date_gmt":"2026-06-30T02:41:44","guid":{"rendered":"https:\/\/regask.com\/?p=10377"},"modified":"2026-06-30T10:41:44","modified_gmt":"2026-06-30T02:41:44","slug":"marktzugang-fur-arzneimittelpreise-juni-2026","status":"publish","type":"post","link":"https:\/\/regask.com\/de\/drug-pricing-market-access-june-2026\/","title":{"rendered":"Arzneimittelpreise und Marktzugang im Jahr 2026: Medicare Neg\u2026"},"content":{"rendered":"<p id=\"ember1956\" class=\"ember-view reader-text-block__paragraph\"><span class=\"TextRun SCXW232482172 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><strong><span class=\"NormalTextRun SCXW232482172 BCX0\">Arzneimittelpreise und Marktzugang verlagerten sich auf\u00a0<\/span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW232482172 BCX0\">Center<\/span><span class=\"NormalTextRun SCXW232482172 BCX0\">\u00a0der Pharmaregulierung Mitte 2026, da sich der Fokus von der Registrierung auf die Finanzierung verlagert.<\/span><span class=\"NormalTextRun SCXW232482172 BCX0\">,<\/span><\/strong><span class=\"NormalTextRun SCXW232482172 BCX0\"><strong>\u00a0Preisgestaltung, Finanzierung und Bewertung von Gesundheitstechnologien.<\/strong> Die USA haben ihren Rahmen f\u00fcr Preisverhandlungen im Rahmen von Medicare weiterentwickelt, Spanien hat eine Konsultation zur Arzneimittelpreisgestaltung eingeleitet, und Portugal\u00a0<\/span><span class=\"NormalTextRun SCXW232482172 BCX0\">formalisiert<\/span><span class=\"NormalTextRun SCXW232482172 BCX0\">\u00a0Ein nationales HTA-Verfahren, alles im selben Monat. Dies ist die Phase im Lebenszyklus, in der ein absolut zulassungsf\u00e4higes Produkt dennoch kommerziell scheitern kann, und die Kluft zwischen Zulassung und Marktzugang vergr\u00f6\u00dfert sich.<\/span><\/span><span class=\"EOP Selected SCXW232482172 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/p>\n\t<div id=\"gap-1907987455\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1907987455 {\n  padding-top: 20px;\n}\n<\/style>\n\t<\/div>\n\t\n<h3><strong><span class=\"TextRun MacChromeBold SCXW167568299 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW167568299 BCX0\">Die USA haben die Verhandlungen \u00fcber Arzneimittelpreise im Rahmen von Medicare ausgeweitet.<\/span><\/span><\/strong><\/h3>\n\t<div id=\"gap-574808891\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-574808891 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"NormalTextRun SCXW16343997 BCX0\">Die Centers for Medicare &amp; Medicaid Services (CMS) haben einen Regelungsvorschlag zum Medicare-Programm zur Verhandlung von Arzneimittelpreisen und zum Medicare-Programm zur Bezahlung von verschreibungspflichtigen Medikamenten ver\u00f6ffentlicht. Seit ihrer Einf\u00fchrung hat die Preisverhandlung die US-amerikanische Wirtschaftsplanung grundlegend ver\u00e4ndert, und jede Erweiterung vergr\u00f6\u00dfert den Handlungsspielraum.\u00a0<\/span><span class=\"NormalTextRun SCXW16343997 BCX0\">Produkte,<\/span><span class=\"NormalTextRun SCXW16343997 BCX0\">\u00a0und die\u00a0<\/span><span class=\"NormalTextRun SCXW16343997 BCX0\">Mechanik&#039;\u2019<\/span><span class=\"NormalTextRun SCXW16343997 BCX0\">\u00a0Die Hersteller m\u00fcssen Modelle entwickeln. Preisstrategie, Markteinf\u00fchrungsreihenfolge und Lebenszyklusplanung jetzt.\u00a0<\/span><span class=\"NormalTextRun SCXW16343997 BCX0\">muss<\/span><span class=\"NormalTextRun SCXW16343997 BCX0\">\u00a0Ber\u00fccksichtigen Sie das Verhandlungsrisiko, anstatt es als seltenen Ausnahmefall zu behandeln. Unternehmen, die fr\u00fchzeitig reagieren, integrieren Verhandlungsszenarien in ihre Prognosen; die \u00fcbrigen sehen sich mit \u00fcberholten Annahmen konfrontiert.<\/span><\/p>\n<h3><strong><span class=\"TextRun MacChromeBold SCXW86240589 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW86240589 BCX0\">Spanien hat Reformen im Bereich Preisgestaltung und Finanzierung eingeleitet.<\/span><\/span><\/strong><\/h3>\n\t<div id=\"gap-525362053\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-525362053 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"NormalTextRun SCXW22514267 BCX0\">Das spanische Gesundheitsministerium hat eine Konsultation zu einem Entwurf f\u00fcr ein k\u00f6nigliches Dekret zur Reform der Arzneimittelpreisgestaltung und -finanzierung eingeleitet. Konsultationen zur Preisreform bergen sowohl Chancen als auch Risiken.\u00a0<\/span><span class=\"NormalTextRun SCXW22514267 BCX0\">(<\/span><span class=\"NormalTextRun SCXW22514267 BCX0\">das Zeitfenster zum Handeln, bevor die Regeln versch\u00e4rft werden<\/span><span class=\"NormalTextRun SCXW22514267 BCX0\">)<\/span><span class=\"NormalTextRun SCXW22514267 BCX0\">, Aber<\/span><span class=\"NormalTextRun SCXW22514267 BCX0\">\u00a0Sie signalisieren au\u00dferdem, dass die H\u00fcrden f\u00fcr die Kostenerstattung neu gesetzt werden. Unternehmen, die bereits auf dem spanischen Markt t\u00e4tig sind oder diesen anvisieren, sollten den Entwurf sorgf\u00e4ltig lesen, die finanziellen Auswirkungen modellieren und die Konsultationsphase nutzen, um ihre Argumente darzulegen. Ein fr\u00fchzeitiges Engagement ist deutlich kosteng\u00fcnstiger als eine nachtr\u00e4gliche Preisanpassung.<\/span><\/p>\n<h3><strong><span class=\"NormalTextRun SCXW80489494 BCX0\">Portugal\u00a0<\/span><span class=\"NormalTextRun SCXW80489494 BCX0\">gegr\u00fcndet<\/span><span class=\"NormalTextRun SCXW80489494 BCX0\">\u00a0ein nationaler HTA-Rahmen<\/span><\/strong><\/h3>\n\t<div id=\"gap-196945414\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-196945414 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"TextRun SCXW253334816 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW253334816 BCX0\">Portugal ver\u00f6ffentlichte das Gesetzesdekret 118\/2026\u00a0<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">Festlegung<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">\u00a0ein nationales System zur Bewertung von Gesundheitstechnologien,\u00a0<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">Formalisierung<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">\u00a0Wie neue Arzneimittel und Technologien auf ihre Erstattungsf\u00e4higkeit hin bewertet werden. HTA ist in Europa zunehmend das eigentliche Zugangstor: Die Zulassung gew\u00e4hrt eine\u00a0<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">Lizenz<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">, Die HTA entscheidet jedoch, ob das System zahlt.\u00a0<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">formalisiert<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">\u00a0Rahmen bedeutet fr\u00fchere, strukturiertere Vorgehensweise\u00a0<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">Beweise f\u00fcr<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">\u00a0<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">Forderungen;<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">\u00a0<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">Gesundheits\u00f6konomische Daten und vergleichende Wirksamkeitsanalysen m\u00fcssen bereits in die Entwicklungsplanung einbezogen werden und d\u00fcrfen nicht erst bei der Markteinf\u00fchrung zusammengetragen werden, wenn Studiendesign und Vergleichsgruppen bereits festgelegt sind.<\/span><\/span><span class=\"EOP SCXW253334816 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/p>\n<h3><strong><span class=\"NormalTextRun SCXW227434142 BCX0\">Was\u00a0<\/span><span class=\"NormalTextRun ContextualSpellingAndGrammarErrorV2Themed SCXW227434142 BCX0\">Das<\/span><span class=\"NormalTextRun SCXW227434142 BCX0\">\u00a0<\/span><span class=\"NormalTextRun ContextualSpellingAndGrammarErrorV2Themed SCXW227434142 BCX0\">bedeutet<\/span><span class=\"NormalTextRun SCXW227434142 BCX0\">\u00a0f\u00fcr\u00a0<\/span><span class=\"NormalTextRun SCXW227434142 BCX0\">Pharma<\/span><\/strong><\/h3>\n\t<div id=\"gap-877508464\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-877508464 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"TextRun SCXW97054545 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW97054545 BCX0\">In den USA, Spanien und Portugal gilt die gleiche Botschaft: Die Genehmigung zu erhalten, ist nicht mehr der schwierigste Teil.<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">,\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">Bezahlt werden ist. Bringen\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">Marktzugang<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">\u00a0Vorausschauend denken. Preisverhandlungen in den USA nach Vorbildern gestalten, Preisberatungen wie in Spanien in Anspruch nehmen.\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">sie sind<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">\u00a0\u00d6ffnen Sie die M\u00e4rkte und sammeln Sie fr\u00fchzeitig HTA-konforme Evidenz f\u00fcr sie.\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">Formalisierung<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">\u00a0Bewertung. Die Zugangsstrategie geh\u00f6rt nun zusammen mit dem klinischen Programm in die Entwicklungsplanung.<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">S<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">, nicht in dem anschlie\u00dfenden Wettlauf nach der Genehmigung, wo\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">Beweise f\u00fcr<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">\u00a0Optionen\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">hat<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">\u00a0bereits eingegrenzt.\u00a0<\/span><strong><a href=\"http:\/\/regask.com\/de\/\"><span class=\"NormalTextRun SpellingErrorV2Themed SCXW97054545 BCX0\">RegASK<\/span><\/a><\/strong><span class=\"NormalTextRun SCXW97054545 BCX0\">\u00a0\u00fcberwacht Preisgestaltung, Kostenerstattung und HTA-Entwicklungen auf globalen M\u00e4rkten und unterst\u00fctzt so die Teams f\u00fcr Zulassung und Marktzugang.\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">planen<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">\u00a0Zugangsbarrieren vor\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">Start<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">.<\/span><\/span><span class=\"EOP SCXW97054545 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>Drug pricing and market access moved to the\u00a0centre\u00a0of pharma regulation in mid-2026, as the focus shifted from registration to money,\u00a0pricing, financing, and health technology assessment. The US advanced its Medicare price-negotiation framework, Spain opened a consultation on drug pricing, and Portugal\u00a0formalized\u00a0a national HTA regime, all in the same month. This is the part of the&#8230;<\/p>","protected":false},"author":46,"featured_media":10378,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-10377","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blogs"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.8 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Drug Pricing and Market Access Explained in 2026<\/title>\n<meta name=\"description\" content=\"Explore the challenges of drug pricing and market access in a changing regulatory landscape. Understand the impact on commercialization.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/de\/marktzugang-fur-arzneimittelpreise-juni-2026\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Drug Pricing &amp; Market Access in 2026: Medicare Negotiation, Spain Reform &amp; Portugal HTA\" \/>\n<meta property=\"og:description\" content=\"Explore the challenges of drug pricing and market access in a changing regulatory landscape. Understand the impact on commercialization.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/de\/marktzugang-fur-arzneimittelpreise-juni-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-30T02:41:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2026\/06\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Shaffa Renaningtyas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Shaffa Renaningtyas\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/\"},\"author\":{\"name\":\"Shaffa Renaningtyas\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/6d86c29c9123b2b67a3ea8e259cdb925\"},\"headline\":\"Drug Pricing &#038; Market Access in 2026: Medicare Neg&hellip;\",\"datePublished\":\"2026-06-30T02:41:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/\"},\"wordCount\":490,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png\",\"articleSection\":[\"Blogs\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/\",\"name\":\"Drug Pricing and Market Access Explained in 2026\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png\",\"datePublished\":\"2026-06-30T02:41:44+00:00\",\"description\":\"Explore the challenges of drug pricing and market access in a changing regulatory landscape. Understand the impact on commercialization.\",\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png\",\"width\":800,\"height\":600,\"caption\":\"Drug Pricing & Market Access In 2026 Medicare Negotiation, Spain Reform & Portugal Hta\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/6d86c29c9123b2b67a3ea8e259cdb925\",\"name\":\"Shaffa Renaningtyas\",\"sameAs\":[\"https:\\\/\\\/regask.com\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Arzneimittelpreise und Marktzugang erkl\u00e4rt im Jahr 2026","description":"Erforschen Sie die Herausforderungen der Arzneimittelpreisgestaltung und des Marktzugangs in einem sich wandelnden regulatorischen Umfeld. Verstehen Sie die Auswirkungen auf die Kommerzialisierung.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/de\/marktzugang-fur-arzneimittelpreise-juni-2026\/","og_locale":"de_DE","og_type":"article","og_title":"Drug Pricing & Market Access in 2026: Medicare Negotiation, Spain Reform & Portugal HTA","og_description":"Explore the challenges of drug pricing and market access in a changing regulatory landscape. Understand the impact on commercialization.","og_url":"https:\/\/regask.com\/de\/marktzugang-fur-arzneimittelpreise-juni-2026\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2026-06-30T02:41:44+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/06\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png","type":"image\/png"}],"author":"Shaffa Renaningtyas","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Shaffa Renaningtyas","Est. reading time":"3\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/#article","isPartOf":{"@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/"},"author":{"name":"Shaffa Renaningtyas","@id":"https:\/\/regask.com\/#\/schema\/person\/6d86c29c9123b2b67a3ea8e259cdb925"},"headline":"Drug Pricing &#038; Market Access in 2026: Medicare Neg&hellip;","datePublished":"2026-06-30T02:41:44+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/"},"wordCount":490,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/06\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png","articleSection":["Blogs"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/","url":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/","name":"Arzneimittelpreise und Marktzugang erkl\u00e4rt im Jahr 2026","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/06\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png","datePublished":"2026-06-30T02:41:44+00:00","description":"Erforschen Sie die Herausforderungen der Arzneimittelpreisgestaltung und des Marktzugangs in einem sich wandelnden regulatorischen Umfeld. Verstehen Sie die Auswirkungen auf die Kommerzialisierung.","inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/drug-pricing-market-access-june-2026\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/06\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/06\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png","width":800,"height":600,"caption":"Drug Pricing & Market Access In 2026 Medicare Negotiation, Spain Reform & Portugal Hta"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Das regulatorische KI-Betriebssystem f\u00fcr leistungsstarke Teams","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/6d86c29c9123b2b67a3ea8e259cdb925","name":"Shaffa Renaningtyas","sameAs":["https:\/\/regask.com\/"]}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/10377","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/users\/46"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/comments?post=10377"}],"version-history":[{"count":3,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/10377\/revisions"}],"predecessor-version":[{"id":10381,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/10377\/revisions\/10381"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/media\/10378"}],"wp:attachment":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/media?parent=10377"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/categories?post=10377"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/tags?post=10377"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}